Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Director | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,863 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 1,800 · Balance 46,863 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 23, 2022 22:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.33 | $72.23 |
DisclosureSEC source: 0001209191-22-062654 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,657 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 30, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.32 | $71.92 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,626 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 29, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.34 | $72.54 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,595 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 28, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.37 | $73.47 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,564 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 25, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.31 | $71.61 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,533 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 23, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.29 | $70.99 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,502 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 22, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.37 | $73.47 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,471 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 21, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.38 | $73.78 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,440 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 18, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.27 | $70.37 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,409 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 17, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.29 | $70.99 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,378 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 16, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.31 | $71.61 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,347 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 15, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.35 | $72.85 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,316 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 14, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.32 | $71.92 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,285 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 11, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.32 | $71.92 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,254 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.37 | $73.47 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,223 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 09, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.37 | $73.47 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,192 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 08, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.42 | $75.02 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,161 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 07, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.45 | $75.95 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,130 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 04, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.42 | $75.02 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 03, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.44 | $75.64 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,068 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 02, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.54 | $78.74 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,037 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| November 01, 2022 Filed Dec 23, 2022 22:04 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.53 | $78.43 |
DisclosureSEC source: 0001209191-22-062645 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,006 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 31, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.54 | $78.74 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 25 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 28, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.52 | $78.12 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 24 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,944 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 27, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.49 | $77.19 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 23 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,913 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 26, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.42 | $75.02 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 22 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,882 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 25, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.44 | $75.64 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 21 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,851 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 24, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.38 | $73.78 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 20 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,820 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 21, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.49 | $77.19 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 19 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,789 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 20, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.44 | $75.64 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 18 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,758 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 19, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.42 | $75.02 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 17 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,727 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 18, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.46 | $76.26 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 16 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,696 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 17, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.33 | $72.23 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 15 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,665 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 14, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.31 | $71.61 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 14 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,634 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 13, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.38 | $73.78 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 13 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,603 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 12, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.49 | $77.19 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 12 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,572 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 11, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.48 | $76.88 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 11 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 10, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.53 | $78.43 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 10 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,510 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 07, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.66 | $82.46 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 9 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,479 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 06, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.65 | $82.15 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 8 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,448 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 05, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.58 | $79.98 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 7 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,417 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 04, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.61 | $80.91 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 6 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,386 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| October 03, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.54 | $78.74 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 5 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,355 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 30, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.61 | $80.91 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 4 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,324 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 29, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.51 | $77.81 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 3 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,293 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 28, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.52 | $78.12 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 2 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,262 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 27, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.57 | $79.67 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 30 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,231 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 27, 2022 Filed Nov 18, 2022 22:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.57 | $79.67 |
DisclosureSEC source: 0001209191-22-057945 · doc4.xml · nonDerivative · entry 1 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,231 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 26, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.49 | $77.19 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 29 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,200 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
| September 23, 2022 Filed Sep 30, 2022 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 31 | $2.55 | $79.05 |
DisclosureSEC source: 0001209191-22-051669 · doc4.xml · nonDerivative · entry 28 Jones James · CIK 0001490829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,169 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.